EUVIMEDEUVIMED entdecken
Kohortenstudie

Real-world experience with lutetium (177Lu) vipivotide tetraxetan (177Lu-PSMA-617) in metastatic castration resistant prostate cancer (mCRPC): Results from the first interim analysis of an observational, multicenter, prospective cohort study

K Herrmann, C la Fougère, T Winkens, A Buck, F Zengerling

Nuklearmedizin - NuclearMedicine · 01.04.2026 · 65 (02) · 150-151

DOI: 10.1055/s-0046-1818306 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2026. Verfasst von K Herrmann und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ziel/Aim: The study goal is to describe routine clinical practice with lutetium ( 177 Lu) vipivotide tetraxetan ( 177 Lu-PSMA-617) in metastatic castration resistant prostate cancer (mCRPC), focusing on health-related quality of life (HRQoL) at different time points. The study aims to complement data of the VISION trial in a real-world population, to depict clinical characteristics and their associations with changes in HRQoL, and to outline the positioning of 177 Lu-PSMA-617 treatment within the therapeutic sequence. Methodik/Methods: This non-interventional study collects primary data from 500 patients diagnosed with mCRPC and treated with 177 Lu-PSMA-617 as per local label in Germany. Data include but are not limited to demographics, clinical characteristics, course of disease, prior cancer therapy and patient questionnaires [Functional Assessment of Cancer Therapy-Prostate (FACT-P), FACT-Radionuclid Therapy (FACT-RNT), and Brief Pain Inventory Short Form (BPI-SF)]. Patients are treated for up to 6 cycles, with continuous data collection during treatment and up to 1 year after end of treatment. Data are analyzed descriptively. Ergebnisse/Results: As of August 21 st, 2025, a total of 196 patients were included in the analysis. Of these, 9 patients (4%) completed treatment and 41 (19%) discontinued treatment prematurely. Reasons for premature discontinuation of treatment were progression (11%), physician decision (2%), adverse event, lack of efficacy, death, subject decision, loss to follow-up, and other reasons (1% each). At baseline, patients were on average 71 years old. 75% of patients had an ECOG of 0 or 1, and the average PSA level was 197 ng/mL. The average time since first metastases was 4 years, and the time since the most recent progression was 3 months. Prior to treatment with 177 Lu-PSMA-617, 39% of patients had received only one androgen receptor pathway inhibitor, and 61% had undergone only one taxane-based chemotherapy regimen. Schlussfolgerungen/Conclusion: This first interim analysis provides initial insights into the clinical characteristics and treatment patterns of patients with mCRPC receiving 177 Lu-PSMA-617 in routine practice in Germany. Further data from the follow-up period will be essential to evaluate changes in HRQoL over time. Publication History Article published online: 02 April 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Herrmann, K., Fougère, C. L., Winkens, T., Buck, A., & Zengerling, F. (2026). Real-world experience with lutetium (177Lu) vipivotide tetraxetan (177Lu-PSMA-617) in metastatic castration resistant prostate cancer (mCRPC): Results from the first interim analysis of an observational, multicenter, prospective cohort study. Nuklearmedizin - NuclearMedicine, 65(02), 150-151. https://doi.org/10.1055/s-0046-1818306

Vancouver

Herrmann K, Fougère CL, Winkens T, Buck A, Zengerling F. Real-world experience with lutetium (177Lu) vipivotide tetraxetan (177Lu-PSMA-617) in metastatic castration resistant prostate cancer (mCRPC): Results from the first interim analysis of an observational, multicenter, prospective cohort study. Nuklearmedizin - NuclearMedicine. 2026;65(02):150-151. doi:10.1055/s-0046-1818306

BibTeX
@article{Herrmann2026,
  author = {Herrmann, K and Fougère, C la and Winkens, T and Buck, A and Zengerling, F},
  title = {Real-world experience with lutetium (177Lu) vipivotide tetraxetan (177Lu-PSMA-617) in metastatic castration resistant prostate cancer (mCRPC): Results from the first interim analysis of an observational, multicenter, prospective cohort study},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2026},
  volume = {65},
  number = {02},
  pages = {150--151},
  doi = {10.1055/s-0046-1818306}
}
Kostenlos starten →